Prolocor

Let's scratch the surface.

In the United States, atherosclerotic cardiovascular disease is a leading cause of death and disability for men, women, and people of most racial and ethnic groups.

let's dig deeper

There is a real unmet need.

Currently, there is no precise diagnostic tool that can effectively guide individualized therapy for patients with cardiovascular disease.

learn more

A big problem set us on an even bigger mission.

Our goal is to develop a more precise method and diagnostic tool for assessing and managing risk in cardiovascular disease.

learn how we plan to fulfill it

Learn how we plan to help cardiovascular patients.

See how our technology will empower physicians.

Meet the future of precision diagnostics.

An innovative diagnostic test that is being developed to help doctors make more informed treatment decisions.

discover our test

Prolocor Announces Appointment of Raymond Russo as Chief Commercial Officer

February 27, 2024

Prolocor Announces $1.7 Million in Bridge Funding

February 20, 2024

Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)